Kabra Drugs FY26 Results: Net profit turns positive at ₹496 lakh

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Net profit turned positive to ₹495.98 lakh in FY26 from a loss of ₹108.56 lakh in FY25
  • Revenue from operations jumped to ₹9,274.00 lakh after resuming trading operations
  • Operating cash flow remained negative at ₹(946.09) lakh due to rising receivables
  • Trade receivables surged to ₹7,077.60 lakh, while cash reserves fell to ₹1,058.23 lakh
  • Company renamed Aanjaay Industries Limited and shifted registered office to Chennai
powered bylight_fuzz_icon
50425387

*this image is generated using AI for illustrative purposes only.

Aanjaay Industries Limited (formerly Kabra Drugs Limited) returned to profitability in FY26, reporting a net profit of ₹495.98 lakh against a net loss of ₹108.56 lakh in FY25. The turnaround was driven by the resumption of commercial activities, which generated revenue from operations of ₹9,274.00 lakh, compared to nil in the preceding year.

The company’s total expenses stood at ₹8,751.20 lakh, dominated by purchases of stock-in-trade amounting to ₹8,366.40 lakh. This cost structure yielded a gross margin of approximately 9.8%. Other income contributed ₹49.27 lakh to the bottom line, primarily from interest income, while tax expenses were recorded at ₹76.09 lakh.

What the Numbers Show

Despite the accounting profit, the company’s operating cash flow was negative at ₹(946.09) lakh. This divergence stems from a significant increase in trade receivables, which rose to ₹7,077.60 lakh from ₹60.05 lakh in the prior year. While trade payables also increased substantially to ₹5,487.98 lakh, the net working capital requirement absorbed cash generated from operations. Cash and cash equivalents declined to ₹1,058.23 lakh from ₹2,129.93 lakh.

Balance Sheet Position

Total assets expanded to ₹8,631.56 lakh from ₹2,522.90 lakh in FY25. Current assets accounted for ₹8,396.84 lakh, largely driven by the receivable buildup. On the liability side, current liabilities rose to ₹5,658.48 lakh, with trade payables constituting the majority. The company maintained a debt-equity ratio of 0.01, with borrowings limited to ₹42.91 lakh, mostly from directors.

Corporate Developments

The company changed its name to Aanjaay Industries Limited effective July 6, 2026, and shifted its registered office to Chennai. The Board appointed Ms. Moonam Kapoor as an independent director and Mrs. Twinkle Agarwal as secretarial auditor for a five-year term. The 37th Annual General Meeting is scheduled for September 30, 2026.

Historical Stock Returns for Kabra Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
+3.52%+5.40%-14.14%-31.62%+13.84%0.0%

How does the company plan to address the significant divergence between accounting profit and negative operating cash flow caused by the sharp rise in trade receivables?

What specific strategies will Aanjaay Industries implement to improve its thin 9.8% gross margin and reduce dependency on high stock-in-trade costs?

Given the substantial increase in current liabilities, what is the management's outlook on debt servicing and liquidity management for the upcoming fiscal year?

Aanjaay Industries sets Sep 30 AGM for director appointments

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Aanjaay Industries schedules 37th AGM for September 30, 2026, in Chennai
  • Shareholders to approve appointment of Ms. Moonam Kapoor as independent director
  • Mrs. Twinkle Agarwal proposed as secretarial auditor for five-year term
  • E-voting opens September 27 with a cut-off date of September 23
powered bylight_fuzz_icon
50346102

*this image is generated using AI for illustrative purposes only.

Aanjaay Industries Limited , formerly known as Kabra Drugs Limited, has scheduled its 37th Annual General Meeting for Wednesday, September 30, 2026. The meeting will be held at the Fairfield by Marriott Hotel in Chennai.

The Board of Directors has filed the notice with BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting aims to transact both ordinary and special business items related to governance and statutory compliance.

Ordinary Business Items

Shareholders will receive, consider, and adopt the Audited Financial Statements for the financial year ended March 31, 2026. Additionally, Mr. Kuniamuthur Nanjappan Anand (DIN: 03230186) retires by rotation and offers himself for re-appointment as a director.

Special Business Items

The primary special resolution seeks shareholder approval to appoint Ms. Moonam Kapoor (DIN: 09278005) as a Non-Executive Independent Director. She was initially appointed as an Additional Non-Executive Independent Director effective April 21, 2026. The proposed term is five consecutive years, ending April 20, 2031.

Ms. Kapoor holds qualifications in BCA and PGDBM and brings five years of directorship experience across listed and private companies. She currently serves on the boards of Plaza Wires Limited, Wonder Electricals Limited, Rajnish Wellness Limited, Finelistings Technologies Limited, and Lorenzini Apparels Limited. Her remuneration for this role is nil.

A second special resolution proposes the appointment of Mrs. Twinkle Agarwal as the Secretarial Auditor. This five-year term covers financial years 2026–2027 through 2030–2031. Her remuneration will be mutually agreed upon between the Board and the auditor.

E-Voting and Logistics

The company has enabled e-voting through Central Depository Services (India) Limited (CDSL). The voting window opens on September 27, 2026, at 9:00 am and closes on September 29, 2026, at 5:00 pm. Shareholders holding shares as on the cut-off date of September 23, 2026, are eligible to vote.

M/s. Jay Jain & Associates has been appointed as the scrutinizer for the e-voting process. Results will be declared on or after the AGM date.

Historical Stock Returns for Kabra Drugs

1 Day5 Days1 Month6 Months1 Year5 Years
+3.52%+5.40%-14.14%-31.62%+13.84%0.0%

How might the appointment of Ms. Moonam Kapoor, with her extensive board experience across multiple listed entities, influence Aanjaay Industries' strategic governance and compliance standards?

What specific operational or financial changes can investors expect to see reflected in the Audited Financial Statements for FY 2026 given the company's recent rebranding from Kabra Drugs?

Could the re-appointment of Mr. Kuniamuthur Nanjappan Anand signal a continuation of the current management strategy, or are there anticipated shifts in leadership dynamics?

More News on Kabra Drugs

1 Year Returns:+13.84%